JP2007535555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007535555A5 JP2007535555A5 JP2007511006A JP2007511006A JP2007535555A5 JP 2007535555 A5 JP2007535555 A5 JP 2007535555A5 JP 2007511006 A JP2007511006 A JP 2007511006A JP 2007511006 A JP2007511006 A JP 2007511006A JP 2007535555 A5 JP2007535555 A5 JP 2007535555A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- formula
- cycloalkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 43
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 25
- 125000001424 substituent group Chemical group 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 16
- -1 nitro, sulfonyl Chemical group 0.000 claims description 15
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 14
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 13
- 150000001408 amides Chemical class 0.000 claims description 13
- 125000001589 carboacyl group Chemical group 0.000 claims description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 10
- 125000004104 aryloxy group Chemical group 0.000 claims description 9
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 9
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 8
- 230000003993 interaction Effects 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 5
- 239000000651 prodrug Substances 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- APEJMQOBVMLION-VOTSOKGWSA-N trans-cinnamamide Chemical compound NC(=O)\C=C\C1=CC=CC=C1 APEJMQOBVMLION-VOTSOKGWSA-N 0.000 claims description 3
- 125000005352 carboxycycloalkyl group Chemical group 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 102100022339 Integrin alpha-L Human genes 0.000 claims 8
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 8
- 201000004681 Psoriasis Diseases 0.000 claims 7
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 5
- GZTFUVZVLYUPRG-IZZDOVSWSA-N (e)-3-(4-tert-butylphenyl)-n-(2,3-dihydro-1,4-benzodioxin-6-yl)prop-2-enamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=C(OCCO2)C2=C1 GZTFUVZVLYUPRG-IZZDOVSWSA-N 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 4
- 230000006052 T cell proliferation Effects 0.000 claims 3
- 238000001516 cell proliferation assay Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims 2
- 229930016911 cinnamic acid Natural products 0.000 claims 2
- 235000013985 cinnamic acid Nutrition 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 2
- 125000003965 isoxazolidinyl group Chemical group 0.000 claims 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010037575 Pustular psoriasis Diseases 0.000 claims 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims 1
- 125000005303 dithiazolyl group Chemical group S1SNC(=C1)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000005956 isoquinolyl group Chemical group 0.000 claims 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- IQZPDFORWZTSKT-UHFFFAOYSA-N nitrosulphonic acid Chemical compound OS(=O)(=O)[N+]([O-])=O IQZPDFORWZTSKT-UHFFFAOYSA-N 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000001185 psoriatic effect Effects 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000002755 pyrazolinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 7
- 102100025390 Integrin beta-2 Human genes 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 4
- 0 *c(c(*)c1*)c(*)c(*)c1S[Al]N* Chemical compound *c(c(*)c1*)c(*)c(*)c1S[Al]N* 0.000 description 2
- 125000004689 alkyl amino carbonyl alkyl group Chemical group 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- MJUHIAWSJRKXSH-UHFFFAOYSA-N 2-pyridin-3-ylacetaldehyde Chemical compound O=CCC1=CC=CN=C1 MJUHIAWSJRKXSH-UHFFFAOYSA-N 0.000 description 1
- URZCVPKXOJQTLC-WGSAOQKQSA-N C1C[C@@H](C(=O)O)CC[C@@H]1NC1=CC=CC(SC=2C(=C(C(C=CC(=O)N3CCOCC3)=CC=2)C(F)(F)F)C(F)(F)F)=C1 Chemical compound C1C[C@@H](C(=O)O)CC[C@@H]1NC1=CC=CC(SC=2C(=C(C(C=CC(=O)N3CCOCC3)=CC=2)C(F)(F)F)C(F)(F)F)=C1 URZCVPKXOJQTLC-WGSAOQKQSA-N 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56583804P | 2004-04-28 | 2004-04-28 | |
| US62027704P | 2004-10-20 | 2004-10-20 | |
| PCT/US2005/014802 WO2005105766A2 (en) | 2004-04-28 | 2005-04-28 | Arylphenylamino-and arylphenylether-sulfide derivatives, useful for the treatment of inflammatory and immune diseases, and pharmaceutical compositions containing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007535555A JP2007535555A (ja) | 2007-12-06 |
| JP2007535555A5 true JP2007535555A5 (enExample) | 2008-06-26 |
Family
ID=34968499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007511006A Withdrawn JP2007535555A (ja) | 2004-04-28 | 2005-04-28 | 炎症性疾患および免疫疾患の処置に有用なアリールフェニルアミノ−およびアリールフェニルエーテル−スルフィド誘導体、およびそれらを含む医薬組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080234271A1 (enExample) |
| EP (1) | EP1740561A2 (enExample) |
| JP (1) | JP2007535555A (enExample) |
| WO (1) | WO2005105766A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5105578B2 (ja) | 2003-11-05 | 2012-12-26 | サーコード バイオサイエンス インコーポレイテッド | 細胞接着のモジュレーター |
| AR057455A1 (es) * | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
| MX2010004281A (es) | 2007-10-19 | 2010-09-10 | Sarcode Corp | Composiciones y metodos para el tratamiento de la retinopatia diabetica. |
| EP3932914A1 (en) | 2015-03-13 | 2022-01-05 | Valo Health, Inc. | Alpha-cinnamide compounds and compositions as hdac8 inhibitors |
| EP3810085A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110922A (en) * | 1998-12-29 | 2000-08-29 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| UA74781C2 (en) * | 1999-04-02 | 2006-02-15 | Abbott Lab | Antiinflammatory and immumosuppressive compounds inhibiting cell adhesion |
-
2005
- 2005-04-28 WO PCT/US2005/014802 patent/WO2005105766A2/en not_active Ceased
- 2005-04-28 EP EP05744450A patent/EP1740561A2/en not_active Withdrawn
- 2005-04-28 JP JP2007511006A patent/JP2007535555A/ja not_active Withdrawn
- 2005-04-28 US US11/579,098 patent/US20080234271A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10899714B2 (en) | 6-aminoisoquinoline compounds | |
| US7671205B2 (en) | 6-aminoisoquinoline compounds | |
| KR101386282B1 (ko) | 스핑고신 키나제 저해제 | |
| EP1542678B1 (en) | 1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID-CB sb 1 /sb RECEPTOR LIGANDS | |
| JP2006517199A5 (enExample) | ||
| JP2009503107A (ja) | スフィンゴシンキナーゼ阻害剤およびそれらの使用方法 | |
| EP1256576A1 (en) | Fused imidazolium derivatives | |
| MX2014003958A (es) | Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas. | |
| AU2006239547A1 (en) | Acetylene derivatives | |
| US20190092789A1 (en) | Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders | |
| AU2022304597A1 (en) | Azetidinyl pyrimidines and uses thereof | |
| KR101307066B1 (ko) | Ｈｄｌ-콜레스테롤 상승제로서 3-트라이플루오로메틸-피라진-2-카복실산 아미드 유도체 | |
| JP2008538779A (ja) | アセチレン誘導体 | |
| US20230339920A1 (en) | Preparation method for and crystal form of 3-aryloxy-3-five-membered heteroarylpropylamine compound | |
| EP0668275A1 (en) | Pyrrolidinone derivatives | |
| JP3786983B2 (ja) | ピロリジノン誘導体 | |
| WO2005105766B1 (en) | Arylphenylamino-and arylphenylether-sulfide derivatives, useful for the treatment of inflammatory and immune diseases, and pharmaceutical compositions containing them | |
| DE3228992A1 (de) | Spirothiazolidindion-derivate, herstellung dieser verbindungen und diese enthaltende pharmazeutische praeparate | |
| US20130065911A1 (en) | N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides | |
| WO2005105766A2 (en) | Arylphenylamino-and arylphenylether-sulfide derivatives, useful for the treatment of inflammatory and immune diseases, and pharmaceutical compositions containing them | |
| CN120513242A (zh) | 一种杂环化合物、药物组合物及其用途 | |
| KR20070107130A (ko) | 카나비노이드 ｃｂ2 수용체 조절제로서의 1ｈ-이미다졸유도체 | |
| CN107304180A (zh) | 苯甲酰胺类衍生物、其制备方法及其在医药上的用途 |